Cover Image
市場調查報告書

Leber遺傳性視神經病變 (LHON) (Leber視神經萎縮 ) :開發中產品分析

Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 325610
出版日期 內容資訊 英文 60 Pages
訂單完成後即時交付
價格
Back to Top
Leber遺傳性視神經病變 (LHON) (Leber視神經萎縮 ) :開發中產品分析 Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Pipeline Review, H2 2017
出版日期: 2017年09月30日 內容資訊: 英文 60 Pages
簡介

Leber遺傳性視神經病變 (LHON) ,是先天性的視覺障礙之一。通常在10∼20多歲發病,但也有幼兒期和中年期以後發病的稀少案例。男性比起女性發病率高。症狀包含了眼睛疼痛和不舒服、發麻、刺痛、視野糊不清等。原因為年齡和抽煙、酒精、抗癌劑、化學藥品相關壓力、部分抗生素和氰基等。

本報告提供Leber遺傳性視神經病變 (LHON) (Leber視神經萎縮 ) 治療藥的開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢等相關的系統性資訊。

目錄

簡介

Leber遺傳性視神經病變 (LHON) (Leber視神經萎縮 )的概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

開發中產品的概要

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

開發中的產品:各企業

研究中的產品:各大學/研究機關

開發治療藥的企業

  • Alkeus Pharmaceuticals, Inc.
  • Biovista Inc.
  • GenSight Biologics S.A.
  • Ixchel Pharma, LLC
  • Khondrion BV
  • Spark Therapeutics, Inc.
  • Stealth BioTherapeutics Inc.

治療藥的評估

  • 單獨療法的情況
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

暫停的計劃

產品開發的里程碑

  • 最新消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9755IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Pipeline Review, H2 2017, provides an overview of the Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) (Ophthalmology) pipeline landscape.

Leber's hereditary optic neuropathy (LHON) is an inherited form of vision loss. This condition usually begins in a person's teens or twenties, rare cases may appear in early childhood or later in adulthood. Males are affected much more often than females. Symptoms include eye pain or discomfort, numbness, tingling and clouding of vision. Predisposing factors include age, tobacco smoke, alcohol, cancer treating drugs, stress related chemicals, some antibiotics and cyanogens.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 3, 2, 3, 1 and 1 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.

Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) (Ophthalmology).
  • The pipeline guide reviews pipeline therapeutics for Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) (Ophthalmology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) (Ophthalmology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) (Ophthalmology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Overview
    • Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Companies Involved in Therapeutics Development
    • Alkeus Pharmaceuticals Inc
    • Biovista Inc
    • GenSight Biologics SA
    • Ixchel Pharma LLC
    • Khondrion BV
    • Mitotech SA
    • Spark Therapeutics Inc
    • Stealth BioTherapeutics Inc
  • Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Drug Profiles
    • BVA-202 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BVA-203 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drug for Lebers Hereditary Optic Neuropathy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • elamipretide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy to Activate ND4 for Leber's Hereditary Optic Neuropathy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GS-010 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GS-011 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IXC-201 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IXC-203 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KH-176 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • plastoquinone decyl triphenylphosphonium bromide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SPK-LHON - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Dormant Projects
  • Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Product Development Milestones
    • Featured News & Press Releases
      • Aug 01, 2017: GenSight Biologics Completes Enrollment of RESCUE Phase III Study of GS010 in the Treatment of Leber's Hereditary Optic Neuropathy
      • Jun 14, 2017: GenSight Biologics Reports Long-Term Positive Safety and Visual Acuity Results at Week 96 in Phase I/II Study of GS010 for the Treatment of Leber's Hereditary Optic Neuropathy
      • May 08, 2017: GenSight Biologics to Present Data on GS010 at the Annual Meeting of ARVO
      • Feb 21, 2017: GenSight Biologics Completes Enrollment of REVERSE Phase III Study of GS010 in the treatment of Leber's Hereditary Optic Neuropathy
      • Dec 20, 2016: GenSight Biologics Reports Sustained Visual Acuity Gain at 78 Weeks in Its Phase I/II Study with GS010 for the Treatment of Leber's Hereditary Optic Neuropathy (LHON)
      • Sep 08, 2016: GenSight Biologics Receives Approval to Include Teenage Patients in RESCUE and REVERSE Phase III Trials with GS010 in Leber's Hereditary Optic Neuropathy
      • Jun 08, 2016: GenSight Biologics Announces Additional Promising Results of Its Phase I/II Study with GS010 for the Treatment of Leber's Hereditary Optic Neuropathy (LHON)
      • Jun 01, 2016: Stealth BioTherapeutics Initiates Phase 2 Study of Elamipretide in Leber's Hereditary Optic Neuropathy
      • Feb 29, 2016: GenSight Biologics Enrolls First Patient in Pivotal Phase III Program of GS010 in Leber's Hereditary Optic Neuropathy
      • Sep 10, 2015: GenSight Biologics Receives IND Acceptance from FDA to Enter Phase III with GS010
      • Dec 15, 2014: New CMO joins Khondrion
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy), H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Pipeline by Alkeus Pharmaceuticals Inc, H2 2017
  • Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Pipeline by Biovista Inc, H2 2017
  • Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Pipeline by GenSight Biologics SA, H2 2017
  • Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Pipeline by Ixchel Pharma LLC, H2 2017
  • Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Pipeline by Khondrion BV, H2 2017
  • Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Pipeline by Mitotech SA, H2 2017
  • Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Pipeline by Spark Therapeutics Inc, H2 2017
  • Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Pipeline by Stealth BioTherapeutics Inc, H2 2017
  • Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Dormant Projects, H2 2017

List of Figures

  • Number of Products under Development for Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy), H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products by Targets, H2 2017
  • Number of Products by Stage and Top 10 Targets, H2 2017
  • Number of Products by Mechanism of Actions, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top